ArticleBlood2008
Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA.
Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Transfusion-related acute lung injury-associated HNA-3a antibodies recognize complex determinants on choline transporter-like protein 2.Transfusion · 2014Trial
- Immune Thrombocytopenia Triggered by Sildenafil-Containing Rhino 69 Platinum 1000: A Case Report.Cureus · 2025Article
- Review: Advances in the Pathogenesis and Treatment of Immune Thrombocytopenia Associated with Viral Hepatitis.Global medical genetics · 2023Review
- The important role of non-covalent drug-protein interactions in drug hypersensitivity reactions.Allergy · 2022Review
- Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia.Journal of clinical medicine · 2020Review
- Biomechanical thrombosis: the dark side of force and dawn of mechano-medicine.Stroke and vascular neurology · 2020Review
- A Case of Hyperacute Severe Thrombocytopenia Occurring Less than 24 Hours after Intravenous Tirofiban Infusion.Case reports in hematology · 2018Article
- Mechanism of quinine-dependent monoclonal antibody binding to platelet glycoprotein IIb/IIIa.Blood · 2015Article
- Expanding the binding model of DITP.Blood · 2015Article
- Platelet-independent methods for detecting antibodies to human platelet antigens.Blood transfusion = Trasfusione del sangue · 2015Article
- Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems.Drug safety · 2015Article
- Article
- Article
- Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.Journal of thrombosis and haemostasis : JTH · 2009Review
- Molecular mimicry and immune thrombocytopenia.Blood · 2009Article
- Drug-induced thrombocytopenia: pathogenesis, evaluation, and management.Hematology. American Society of Hematology. Education Program · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Drug-induced immune thrombocytopenia is caused by drug-dependent antibodies (DDAbs) that bind tightly to platelet glycoproteins only when drug is present. How drugs mediate this interaction is not yet resolved. Several studies indicate that sites recognized by DDAbs tend to cluster in specific structural domains, suggesting they may recognize a limited number of distinct epitopes. To address this issue, we characterized the binding sites for 16 quinine-dependent antibodies thought on the basis of preliminary studies to be possibly specific for a single epitope on glycoprotein IIIa (GPIIIa). Fourteen of the antibodies reacted with a 29-kDa GPIIIa fragment comprising only the GPIIIa hybrid and plextrin-semaphorin-integrin homology domains. However, studies with mutant GPIIIa and the blocking monoclonal antibody AP3 showed that the 14 DDAbs recognize at least 6 and possibly more distinct, but overlapping, structures involving GPIIIa residues 50 to 66. The findings suggest that even antibodies specific for restricted domains on a target glycoprotein may each have a slightly different fine specificity; ie, "unique" epitopes recognized by DDAbs may be rare or nonexistent. The observations are consistent with a recently proposed model in which drug reacts noncovalently with both target protein and antibody to promote binding of an otherwise nonreactive immunoglobulin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.